中晚期卵巢癌术后顺铂腹腔联合紫杉醇静脉化疗的临床观察.pdf

《中晚期卵巢癌术后顺铂腹腔联合紫杉醇静脉化疗的临床观察.pdf》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、茅伟，等中晚期卵巢癌术后顺铂腹腔联合紫杉醇静脉化疗的临床观察《临床应用研究／论著l中晚期卵巢癌术后顺铂腹腔联合紫杉醇静脉化疗的临床观察茅伟，邱慧敏，余根培，钱红，王辉，刘卫星，许青同济大学附属第十人民医院肿瘤科，上海200072【摘要】目的：观察顺铂腹腔联合紫杉醇静脉化疗治疗中晚期卵巢癌术后患者的临床疗效和安全性。方法：回顾性分析我院2006一O1—2009—12行细胞减灭术Ⅱ～Ⅳ期卵巢癌76例患者，顺铂腹腔联合紫杉醇静脉化疗36例为治疗组，并以同期行顺铂联合紫杉醇静脉化疗患者4O例作为对照。比较两组患者无进展生存期(PFS)、生存率和不良反应。结果：治疗组PFS27个月，

2、对照组PFS23个月，P<0．05。治疗组l、2和3年生存率分别为97．22(35／36)、94．44(34／36)和88．88％(32／36)，对照组1、2和3年生存率分别为95．。0(38／40)、90．O0(36／40)和77．5O％(31／40)。治化疗组呕吐及肾功能损伤低于对照组，而腹痛高于对照组。结论：顺铂腹腔联合紫杉醇静脉化疗治疗中晚期卵巢癌术后患者可延长患者PFS及生存率，毒副反应轻，值得临床应用。中华肿瘤防治杂志，2012，19(5)：372—374【关键词】卵巢肿瘤／外科学；卵巢肿瘤／药物疗法；药物疗法，联合ClinicalefectofpOstOper

3、atiVeintraperitOneaIchemotherapywithcisplatincombinedwithintravenouspaclitaxelchemotherapyforthemoderatelyoradvancedovariancancerMAOWei，QIUHui—min，y【，Gen—pei，QIANHong，WANGHui，LJUWei—xing，XUQingDepartmentofOncology，No．10People’SHospitalofTongJiUniversity，Shanghai200070，P．R．China[ABSTRACT]OB

4、JECTIVE：Toobservetheclinicalefficacyandsafetyofpostoperativeintraperit0nea1chemotherapywithcisplatincombinedwithintravenouspaclitaxelchemotherapyforthemoderatelyoradvancedovariancancer．METH—ODS：FromJan．2006toDec．2009，76patientswithovariancancerin1I—IVstageaftercytoreductivesurgerywereana—l

5、yzedretrospective1y．And36ovariancancerpatientsweretreatedwithintraperitonealcisplatinchemotherapyandintrave—nouspaclitaxelchemotherapy(treatmentgroup)．Totally40ovariancancerpatientsacceptedintravenouschemotherapywithcisplatinandpaclitaxel(controlgroup)．Theprogressionfreesurvival(PFS)，survi

6、valrateandadversereactionoftwogroupswereobserved．RESULTS：ThePFSintreatmentgroupwas27months，ThePFSincontrolgroupwas23months，thedifferenceswassignificant(P<0．05)．One，twoandthreeyearsurviva1ratesintreatmentandcontrolgroupwere97．22(35／36)，94．44(34／36)and88．88(32／36)respectively，thatinIVgroupwe

7、re95．O0(38／40)，9O．OO(36／40)and77．50％(31／40)respectively．Vomitingandrenalfunctionfailurewasobviouslylowerandstomach—achewasobviouslyhigherinintraperitonealandintravenouschemotherapygroupthanthecontrolgroup．CONCLUSION：Thepostoperativeintraperitonealcisplatinchem